MA29663B1 - Modification du facteur fviii en fonction du site - Google Patents
Modification du facteur fviii en fonction du siteInfo
- Publication number
- MA29663B1 MA29663B1 MA29972A MA29972A MA29663B1 MA 29663 B1 MA29663 B1 MA 29663B1 MA 29972 A MA29972 A MA 29972A MA 29972 A MA29972 A MA 29972A MA 29663 B1 MA29663 B1 MA 29663B1
- Authority
- MA
- Morocco
- Prior art keywords
- site
- modification
- factor according
- fviii
- fviii factor
- Prior art date
Links
- 102100026735 Coagulation factor VIII Human genes 0.000 title abstract 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 title abstract 2
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 108010054218 Factor VIII Proteins 0.000 abstract 1
- 102000001690 Factor VIII Human genes 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 229920000249 biocompatible polymer Polymers 0.000 abstract 1
- 229960000301 factor viii Drugs 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000002947 procoagulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Abstract
Cette invention concerne des mutéines du facteur VIII qui sont liées de manière covalente, sur un site prédéfini autre qu'un N-terminal aminé, à un ou plusieurs polymères biocompatibles tels que le polyéthylène glycol. Les conjugués de mutéine maintiennent l'activité procoagulante du facteur FVIII et possèdent des propriétés pharmacocinétiques améliorées.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62727704P | 2004-11-12 | 2004-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29663B1 true MA29663B1 (fr) | 2008-08-01 |
Family
ID=36337298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA29972A MA29663B1 (fr) | 2004-11-12 | 2007-06-06 | Modification du facteur fviii en fonction du site |
Country Status (32)
Country | Link |
---|---|
US (4) | US7632921B2 (fr) |
EP (9) | EP2772500B1 (fr) |
JP (5) | JP2008524117A (fr) |
KR (7) | KR20180110192A (fr) |
CN (6) | CN103102406B (fr) |
AU (1) | AU2005304622B2 (fr) |
BR (2) | BR122016022033B8 (fr) |
CA (1) | CA2586379C (fr) |
CY (3) | CY1119292T1 (fr) |
DK (3) | DK2363414T3 (fr) |
ES (4) | ES2633916T3 (fr) |
FR (1) | FR19C1031I2 (fr) |
HK (3) | HK1117875A1 (fr) |
HN (1) | HN2007015683A (fr) |
HR (2) | HRP20180481B1 (fr) |
HU (5) | HUE033776T2 (fr) |
IL (3) | IL182903A (fr) |
LT (5) | LT2371856T (fr) |
LU (1) | LUC00118I2 (fr) |
MA (1) | MA29663B1 (fr) |
MX (2) | MX2007005466A (fr) |
NL (1) | NL300989I2 (fr) |
NO (3) | NO20210454A1 (fr) |
NZ (1) | NZ555032A (fr) |
PH (2) | PH12014500352A1 (fr) |
PL (3) | PL1824988T3 (fr) |
PT (4) | PT1824988T (fr) |
RU (1) | RU2423380C2 (fr) |
SI (4) | SI2363414T1 (fr) |
UA (1) | UA95225C2 (fr) |
WO (1) | WO2006053299A2 (fr) |
ZA (1) | ZA200703696B (fr) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2338333B1 (fr) | 2003-04-09 | 2017-09-06 | ratiopharm GmbH | Méthode de glycopegylation et proteines/peptides produits au moyen de ces méthodes |
WO2005012484A2 (fr) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Conjugues anticorps-toxines |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
WO2006005058A2 (fr) | 2004-06-30 | 2006-01-12 | Nektar Therapeutics Al, Corporation | Conjugues polymere-fraction facteur ix |
WO2006010143A2 (fr) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon [glp-1] |
SI2586456T1 (sl) | 2004-10-29 | 2016-05-31 | Ratiopharm Gmbh | Preoblikovanje in glikopegliacija fibroblastnega rastnega faktorja (FGF) |
WO2006053299A2 (fr) | 2004-11-12 | 2006-05-18 | Bayer Healthcare Llc | Modification du facteur fviii en fonction du site |
EP1858543B1 (fr) | 2005-01-10 | 2013-11-27 | BioGeneriX AG | Facteur de stimulation de colonie de granulocytes glycopegylé |
WO2006121569A2 (fr) | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions et methodes utilisees pour la preparation de mutants par glycosylation de l'hormone de croissance humaine resistant a la protease |
EP2360170A3 (fr) | 2005-06-17 | 2012-03-28 | Novo Nordisk Health Care AG | Réduction et dérivatisation de protéines obtenues par génie génétique comprenant au moins une cystéine non native |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
US20090252720A1 (en) * | 2006-05-24 | 2009-10-08 | Novo Nordisk Health Care Ag | Prolonged FIX Analogues and Derivatives |
CN101516388B (zh) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
EP2054521A4 (fr) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | Méthodes de purification de conjugués de polypeptides |
DK2101821T3 (da) | 2006-12-15 | 2014-10-06 | Baxter Healthcare Sa | Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo |
ES2406267T3 (es) | 2007-04-03 | 2013-06-06 | Biogenerix Ag | Métodos de tratamiento usando G-CSF glicopegilado |
WO2008154639A2 (fr) | 2007-06-12 | 2008-12-18 | Neose Technologies, Inc. | Procédé amélioré pour la production de sucres de nucléotide |
KR20100095441A (ko) * | 2007-11-09 | 2010-08-30 | 백스터 인터내셔널 인코포레이티드 | 변형된 재조합 인자 ⅷ 및 폰 빌레브란트 인자 및 사용 방법 |
PL2257311T3 (pl) * | 2008-02-27 | 2014-09-30 | Novo Nordisk As | Koniugaty cząsteczek czynnika VIII |
CN102112144A (zh) | 2008-05-16 | 2011-06-29 | 拜耳医药保健有限公司 | 靶向性凝固因子及其使用方法 |
KR20110017420A (ko) * | 2008-06-04 | 2011-02-21 | 바이엘 헬스케어 엘엘씨 | 폰 빌레브란트 질환의 치료를 위한 fviii 뮤테인 |
KR101648734B1 (ko) | 2008-06-24 | 2016-08-18 | 체에스엘 베링 게엠베하 | 연장된 생체내 반감기를 갖는 인자 viii, 폰 빌레브란트 인자 또는 이들의 복합체 |
WO2010019263A2 (fr) * | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Produits de construction de flt soluble pour traiter des cancers |
KR20110071012A (ko) * | 2008-10-17 | 2011-06-27 | 백스터 인터내셔널 인코포레이티드 | 낮은 수준의 수용성 중합체를 포함하는 개질된 혈액 인자 |
EP2352515A4 (fr) * | 2008-11-03 | 2012-04-25 | Bayer Healthcare Llc | Procédé de traitement de l'hémophilie |
JP2012510060A (ja) * | 2008-11-24 | 2012-04-26 | バイエル・ヘルスケア・エルエルシー | シリカをベースとする活性化部分トロンボプラスチン時間アッセイにおけるpeg化血液凝固因子の活性の測定方法 |
EP2387413A4 (fr) * | 2009-01-19 | 2015-12-23 | Bayer Healthcare Llc | Conjugué protéique ayant une fraction bio-protectrice pouvant être clivée par une endopeptidase |
MX362028B (es) | 2009-02-03 | 2019-01-04 | Amunix Pharmaceuticals Inc | Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos. |
CN102333788A (zh) * | 2009-02-19 | 2012-01-25 | 诺沃—诺迪斯克有限公司 | 因子viii的修饰 |
EP2408800B1 (fr) * | 2009-03-20 | 2016-05-25 | Hanmi Science Co., Ltd. | Procédé de préparation d'un conjugué site-spécifié d'un polypeptide physiologiquement actif |
CN102427823A (zh) * | 2009-03-24 | 2012-04-25 | 拜耳医药保健有限公司 | 因子viii变体及使用方法 |
JP5908401B2 (ja) | 2009-07-27 | 2016-04-26 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 血液凝固タンパク質複合体 |
HUE028056T2 (en) | 2009-07-27 | 2016-11-28 | Baxalta GmbH | Blood coagulation protein conjugates |
WO2011012850A2 (fr) | 2009-07-27 | 2011-02-03 | Lipoxen Technologies Limited | Glyco-polysialylation de protéines de coagulation non sanguine |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
AU2010290077C1 (en) * | 2009-08-24 | 2015-12-03 | Bioverativ Therapeutics Inc. | Coagulation factor IX compositions and methods of making and using same |
ES2880038T3 (es) | 2009-12-06 | 2021-11-23 | Bioverativ Therapeutics Inc | Polipéptidos quiméricos e híbridos de factor VIII-Fc, y métodos de uso de los mismos |
US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
CN102770449B (zh) | 2010-02-16 | 2016-02-24 | 诺沃—诺迪斯克有限公司 | 具有降低的vwf结合的因子viii分子 |
RS59827B1 (sr) * | 2010-02-21 | 2020-02-28 | Bayer Healthcare Llc | Metoda za aktiviranje i konjugovanje biomolekula |
CN106432557A (zh) | 2010-04-15 | 2017-02-22 | 科迪亚科学企业公司 | 高分子量的含两性离子的聚合物 |
GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
GB201007357D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
WO2012006623A1 (fr) * | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Systèmes pour le traitement du facteur viii et procédés associés |
EP2635297B1 (fr) * | 2010-11-05 | 2019-02-27 | Baxalta GmbH | Un nouveau variant du facteur viii anti-hémophile ayant une activité spécifique accrue |
JP2014501227A (ja) * | 2010-12-16 | 2014-01-20 | ノヴォ ノルディスク アー/エス | 第viii因子水溶液 |
CA2822591C (fr) | 2010-12-22 | 2020-12-29 | Baxter International Inc. | Materiels et methodes pour la conjugaison d'un derive d'acide gras soluble dans l'eau a une proteine |
AU2012262428C1 (en) * | 2011-05-27 | 2018-10-11 | Takeda Pharmaceutical Company Limited | Therapeutic proteins with increased half-life and methods of preparing same |
PL2717898T3 (pl) | 2011-06-10 | 2019-06-28 | Bioverativ Therapeutics Inc. | Związki o działaniu prokoagulacyjnym i sposoby ich stosowania |
CN103930440A (zh) | 2011-07-01 | 2014-07-16 | 拜耳知识产权有限责任公司 | 松弛素融合多肽及其用途 |
RS58578B1 (sr) | 2011-07-08 | 2019-05-31 | Bioverativ Therapeutics Inc | Faktor viii himernih i hibridnih polipeptida i postupci za njihovu upotrebu |
CA2849673A1 (fr) | 2011-09-23 | 2013-03-28 | Novo Nordisk A/S | Nouveaux analogues du glucagon |
KR20130049671A (ko) * | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
ES2771208T3 (es) | 2012-02-15 | 2020-07-06 | Bioverativ Therapeutics Inc | Composiciones de factor VIII y métodos de preparación y uso de las mismas |
EP2814502B1 (fr) | 2012-02-15 | 2017-09-13 | CSL Behring GmbH | Variants du facteur de von willebrand ayant une affinité de liaison au facteur viii améliorée |
EP3549953A1 (fr) | 2012-02-15 | 2019-10-09 | Bioverativ Therapeutics Inc. | Protéines de facteur viii de recombinaison |
EP2666782A1 (fr) | 2012-05-22 | 2013-11-27 | Imnate Sarl | Facteur VIII de coagulation avec immunogénicité réduite |
CA2875246A1 (fr) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Composes pro-coagulants |
EP2870250B2 (fr) | 2012-07-06 | 2022-06-29 | Bioverativ Therapeutics Inc. | Lignée cellulaire exprimant des polypeptides de facteur viii à une seule chaîne et ses utilisations |
EP2908847B1 (fr) | 2012-10-18 | 2022-03-30 | Bioverativ Therapeutics Inc. | Procédés d'utilisation d'une dose fixe d'un facteur de coagulation |
WO2014070953A1 (fr) | 2012-10-30 | 2014-05-08 | Biogen Idec Ma Inc. | Procédés d'utilisation du polypeptide fviii |
LT2968477T (lt) | 2013-03-15 | 2020-03-10 | Bioverativ Therapeutics Inc. | Faktoriaus viii polipeptido kompozicijos |
US20160030524A1 (en) * | 2013-03-15 | 2016-02-04 | Bayer Healthcare Llc | Recombinant factor viii formulations |
AU2014228938B2 (en) | 2013-03-15 | 2019-05-02 | Bioverativ Therapeutics Inc. | Factor IX polypeptide formulations |
KR20160021758A (ko) | 2013-04-18 | 2016-02-26 | 노보 노르디스크 에이/에스 | 의학용으로 사용하기 위한 안정하고 연장된 glp-1/글루카곤 수용체 코-아고니스트 |
EP2796145B1 (fr) | 2013-04-22 | 2017-11-01 | CSL Ltd. | Un complexe covalent de facteur von willebrand et de faktor viii conjugé par un pont disulfure |
TW201519900A (zh) * | 2013-04-28 | 2015-06-01 | Bayer Healthcare Llc | 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法 |
WO2015023894A1 (fr) | 2013-08-14 | 2015-02-19 | Biogen Idec Ma Inc. | Protéines de facteur viii de recombinaison |
WO2015023891A2 (fr) | 2013-08-14 | 2015-02-19 | Biogen Idec Ma Inc. | Fusions de facteur vii-xten et leurs utilisations |
WO2015035342A2 (fr) | 2013-09-08 | 2015-03-12 | Oligasis Llc | Conjugués polymère zwittérionique-facteur viii |
EP3060242A1 (fr) * | 2013-10-22 | 2016-08-31 | DBV Technologies | Procédé pour traiter l'hémophilie en induisant une tolérance de facteurs sanguins |
EP3065769A4 (fr) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Composé de fusion procoagulant |
RU2546297C1 (ru) * | 2013-11-19 | 2015-04-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук | Средство, улучшающее реологические свойства крови |
ES2967617T3 (es) | 2013-12-06 | 2024-05-03 | Bioverativ Therapeutics Inc | Herramientas de farmacocinética poblacional y sus usos |
RU2695428C2 (ru) * | 2014-01-20 | 2019-07-23 | Октафарма Аг | СПОСОБ ПРОИЗВОДСТВА ФАКТОРА VIII, ИМЕЮЩЕГО УЛУЧШЕННОЕ СООТНОШЕНИЕ FVIII:C/FVIII:Ag |
KR102382402B1 (ko) | 2014-02-04 | 2022-04-01 | 바이오젠 엠에이 인코포레이티드 | 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도 |
EP3114138B1 (fr) | 2014-03-05 | 2021-11-17 | Pfizer Inc. | Mutéines améliorées du facteur viii de coagulation |
MX2016012447A (es) | 2014-03-24 | 2017-01-06 | Biogen Ma Inc | Formulaciones de factor ix liofilizadas. |
US11181534B2 (en) * | 2014-04-04 | 2021-11-23 | Bloodworks | Routine laboratory and point-of-care (POC) testing for hemostasis |
WO2015157335A1 (fr) | 2014-04-10 | 2015-10-15 | Bayer Healthcare Llc | Formulation de poudre de milieux mélangés et procédé de préparation de milieu liquide pour la culture cellulaire |
US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
DK3164150T3 (da) | 2014-07-02 | 2021-02-08 | CSL Behring Lengnau AG | Modificeret von willebrand-faktor |
MA40864A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères |
US11155601B2 (en) | 2015-03-06 | 2021-10-26 | CSL Behring Lengnau AG | Modified von Willebrand factor having improved half-life |
EP3298036B1 (fr) | 2015-05-22 | 2022-04-06 | CSL Behring Lengnau AG | Procédés de préparation du facteur willebrand modifié |
JP6573989B2 (ja) | 2015-05-22 | 2019-09-11 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 血友病を処置するための切断型フォン・ヴィルブランド因子ポリペプチド |
EA201890423A1 (ru) | 2015-08-03 | 2018-07-31 | Биовератив Терапьютикс Инк. | Слитые белки фактора ix, способы их получения и применения |
US9849125B1 (en) | 2015-11-03 | 2017-12-26 | Banner Lifie Sciences LLC | Anti-overingestion dosage forms |
SG11201805497QA (en) | 2016-01-07 | 2018-07-30 | Csl Behring Recombinant Facility Ag | Mutated truncated von willebrand factor |
SG10201912857XA (en) | 2016-01-07 | 2020-02-27 | CSL Behring Lengnau AG | Mutated von willebrand factor |
CN109689683A (zh) * | 2016-06-24 | 2019-04-26 | 财团法人牧岩生命科学研究所 | 重组单链fvⅲ及其化学缀合物 |
DK3538133T3 (da) | 2016-11-11 | 2021-04-19 | CSL Behring Lengnau AG | Trunkeret von willebrand faktor polypeptider til behandling af hæmofili |
JP2020504082A (ja) | 2016-11-11 | 2020-02-06 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド |
BR112019010034A2 (pt) | 2016-11-16 | 2019-09-03 | Bayer Healthcare Llc | fator viii alvejado de hemácia e método de uso do mesmo |
BR112019011198A2 (pt) | 2016-12-02 | 2019-12-17 | Bioverativ Therapeutics Inc | métodos de indução de tolerância imune a fatores de coagulação |
BR112019011115A2 (pt) | 2016-12-02 | 2019-10-01 | Bioverativ Therapeutics Inc | métodos para tratar artropatia hemofílica usando fatores de coagulação quiméricos |
AU2018215092A1 (en) | 2017-01-31 | 2019-08-29 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
KR20190086269A (ko) * | 2018-01-12 | 2019-07-22 | 재단법인 목암생명과학연구소 | 체내 지속형 재조합 당단백질 및 이의 제조방법 |
JP2021523878A (ja) | 2018-05-18 | 2021-09-09 | バイオベラティブ セラピューティクス インコーポレイテッド | 血友病aを処置する方法 |
JP2022553640A (ja) | 2019-10-10 | 2022-12-26 | コディアック サイエンシーズ インコーポレイテッド | 眼障害を処置する方法 |
WO2021091881A1 (fr) * | 2019-11-04 | 2021-05-14 | The Trustees Of Columbia University In The City Of New York | Compositions de conjugués d'inhibiteurs de caspase de pénétration cellulaire à concentration élevée et procédés associés |
EP4069269A4 (fr) * | 2019-12-06 | 2023-12-27 | The Children's Hospital Of Philadelphia | Compositions et procédés de modulation de la fonction du facteur viii |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59172425A (ja) * | 1983-03-18 | 1984-09-29 | Nippon Chemiphar Co Ltd | 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤 |
US7138505B1 (en) | 1984-01-12 | 2006-11-21 | Novartis Vaccines And Diagnostics, Inc. | Factor VIII:C nucleic acid molecules |
US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
US5422260A (en) | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
US5451521A (en) | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
US5171844A (en) | 1987-06-12 | 1992-12-15 | Gist-Brocades N.W. | Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
EP0690126B1 (fr) | 1987-06-12 | 2001-11-28 | Baxter Aktiengesellschaft | Protéines à activité de facteur VIII, procédé pour leur production utilisant des cellules modifiées par génie génétique et compositions pharmaceutiques les contenant |
US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
AU2473388A (en) * | 1987-11-16 | 1989-06-22 | Scripps Clinic And Research Foundation | Treatment of factor viii inhibitors |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
US6037452A (en) | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
DK0627924T3 (da) | 1992-10-02 | 2001-04-30 | Genetics Inst | Sammensætning, der omfatter koagulationsfaktor VIII formulering, fremgangsmåde til dens fremstilling og anvendelse af et overfladeaktivt middel som stabilisator |
WO1994015625A1 (fr) * | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Conjugues de polymere et de facteur viii |
SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
EP0730660A4 (fr) | 1993-10-29 | 1998-02-25 | Incyte Pharma Inc | Proteines chimeres contenant des variantes de la protease nexine-1 |
IL113010A (en) | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
BE1008491A3 (fr) * | 1994-07-14 | 1996-05-07 | Croix Rouge De Belgique Depart | Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci. |
EP0788375A2 (fr) | 1994-11-09 | 1997-08-13 | Robin Ewart Offord | Polymeres fonctionnalises destines a une ligation dirigee |
AU691111B2 (en) * | 1995-06-21 | 1998-05-07 | Google Technology Holdings LLC | Method and antenna for providing an omnidirectional pattern |
WO1997003195A1 (fr) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Nouveaux analogues polypeptidiques de facteur viii:c ayant des sites de protease modifies |
SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
AT403438B (de) | 1996-05-24 | 1998-02-25 | Immuno Ag | Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität |
US6458563B1 (en) * | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
RU2199347C2 (ru) * | 1996-08-02 | 2003-02-27 | Орто-Макнейл Фармасьютикал, Инк. | Полипептиды, обладающие единственным ковалентно связанным n-концевым водорастворимым полимером |
CA2225189C (fr) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Gene et proteine du facteur viii du chien et methodes d'utilisation |
ATE375363T1 (de) | 1997-07-14 | 2007-10-15 | Bolder Biotechnology Inc | Derivate des wachstumshormons und verwandte proteine |
US6753165B1 (en) * | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
WO1999020288A1 (fr) * | 1997-10-17 | 1999-04-29 | Harvest Technologies Corporation | Precipitation d'un concentre de fibrinogene enrichi d'un facteur de croissance obtenue a partir d'un plasma enrichi aux plaquettes |
EP0922446A1 (fr) | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Préparation des conjugués du GRF-PEG par un méthode en solution spécifique à un site |
PT1079805E (pt) | 1998-04-27 | 2005-03-31 | Opperbas Holding Bv | Composicao farmaceutica compreendendo factor viii e lipossomas neutros |
US6759216B1 (en) | 1998-11-06 | 2004-07-06 | Emory University | Glycosylated, low antigenicity low immunogenicity factor VIII |
DK1129186T4 (da) | 1998-11-10 | 2017-02-06 | Stichting Sanquin Bloedvoorziening | Et faktor VIII-polypeptid med faktor VIII:C-aktivitet |
US6136599A (en) | 1998-12-10 | 2000-10-24 | Bayer Corporation | Human hybrid host cell for mammalian gene expression |
US6358703B1 (en) | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
IL144259A0 (en) | 1999-01-14 | 2002-05-23 | Bolder Biotechnology Inc | Methods for making proteins containing free cysteine residues |
WO2000071714A2 (fr) | 1999-05-24 | 2000-11-30 | The American National Red Cross | Procedes de reduction de la clairance du facteur viii et compositions correspondantes |
RU2278123C2 (ru) * | 2000-02-11 | 2006-06-20 | Максиджен Холдингз Лтд. | Молекулы, подобные фактору vii или viia |
JP2004525608A (ja) | 2000-09-19 | 2004-08-26 | エモリー ユニバーシテイ | 修飾された因子viii |
JP2005518181A (ja) | 2001-01-12 | 2005-06-23 | ジ・アメリカン・ナショナル・レッド・クロス | 第viii因子のヘパラン硫酸プロテオグリカン仲介性クリアランスを低下させるための方法および組成物 |
AU2002249096B2 (en) * | 2001-03-22 | 2007-06-28 | Novo Nordisk Health Care Ag | Coagulation factor VII derivatives |
WO2002098454A2 (fr) | 2001-05-31 | 2002-12-12 | D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven | Molecules recombinees a immunogenicite reduite, procedes et produits intermediaires pour les obtenir et leur utilisation dans des compositions pharmaceutiques et des outils diagnostiques |
WO2002096454A1 (fr) | 2001-05-31 | 2002-12-05 | D. Collen Research Foundation Vzw | Molecules recombinees avec immunogenicite reduite, procedes et intermediaires permettant d'obtenir ces molecules, et utilisation de ces molecules dans des compositions pharmaceutiques et des outils diagnostiques |
ES2331909T3 (es) | 2001-06-14 | 2010-01-20 | The Scripps Research Institute | Factor viii estabilizado con enlaces disulfuro modificados geneticamente. |
CA2461443C (fr) | 2001-10-05 | 2011-07-12 | Emory University | Sequences d'acides nucleiques et d'acides amines codant des polypeptides de facteur viii a expresseur a haut rendement et leurs procedes d'utilisation |
BR0308860A (pt) | 2002-04-18 | 2005-01-04 | Merck Patent Gmbh | Fator viii modificado |
JP4412461B2 (ja) | 2002-11-20 | 2010-02-10 | 日油株式会社 | 修飾された生体関連物質、その製造方法および中間体 |
US8003117B2 (en) | 2002-11-20 | 2011-08-23 | Nof Corporation | Polyalkylene glycol derivative and modified bio-related substance |
WO2004060965A2 (fr) | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Polymeres a terminaison maleimide hydrolytiquement stables |
ES2308032T5 (es) | 2002-12-31 | 2017-04-24 | Nektar Therapeutics | Derivados poliméricos de ácido maleámico y sus bioconjugados |
KR101207247B1 (ko) | 2003-01-06 | 2012-12-03 | 넥타르 테라퓨틱스 | 티올-선택성 수용성 중합체 유도체 |
CN1767857A (zh) * | 2003-02-26 | 2006-05-03 | 尼克塔治疗亚拉巴马公司 | 聚合物-因子ⅷ部分共轭物 |
US20040180054A1 (en) * | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
US20050176108A1 (en) * | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
KR20060028675A (ko) * | 2003-05-12 | 2006-03-31 | 아피맥스, 인크. | 신규한 폴리 (에틸렌 글리콜) 개질 화합물 및 그의 용도 |
EP2644206B1 (fr) | 2003-05-23 | 2019-04-03 | Nektar Therapeutics | Derives du PEG qui contiennent deux chaînes de PEG |
EP1502921A1 (fr) | 2003-07-29 | 2005-02-02 | ZLB Behring GmbH | Mutants du Facteur VIII (FVIII) humain recombinants ayant une meilleure stabilité |
WO2005046583A2 (fr) | 2003-10-30 | 2005-05-26 | Emory University | Facteur fviii modifie presentant une immunogenicite reduite par mutagenese d'epitopes a2 et c2 |
US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
WO2005055930A2 (fr) | 2003-12-03 | 2005-06-23 | University Of Rochester | Facteur viii recombine presentant une activite specifique amelioree |
WO2006027111A1 (fr) | 2004-09-06 | 2006-03-16 | Zlb Behring Gmbh | Facteur viii de coagulation modifie presentant une meilleure stabilite |
WO2006053299A2 (fr) | 2004-11-12 | 2006-05-18 | Bayer Healthcare Llc | Modification du facteur fviii en fonction du site |
EP1871801A2 (fr) | 2005-04-01 | 2008-01-02 | Novo Nordisk Health Care AG | Analogues du fviii de coagulation sanguine |
CA2647314A1 (fr) * | 2006-03-31 | 2007-11-08 | Baxter International Inc. | Facteur viii pegyle |
US7645860B2 (en) * | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
-
2005
- 2005-11-14 WO PCT/US2005/041205 patent/WO2006053299A2/fr active Search and Examination
- 2005-11-14 HU HUE05849392A patent/HUE033776T2/en unknown
- 2005-11-14 HU HUE16186901A patent/HUE050542T2/hu unknown
- 2005-11-14 EP EP14165736.1A patent/EP2772500B1/fr not_active Revoked
- 2005-11-14 HR HRP20180481AA patent/HRP20180481B1/hr active IP Right Grant
- 2005-11-14 EP EP11153300.6A patent/EP2363414B1/fr active Active
- 2005-11-14 KR KR1020187027821A patent/KR20180110192A/ko not_active Application Discontinuation
- 2005-11-14 EP EP16186901.1A patent/EP3130601B1/fr active Active
- 2005-11-14 KR KR1020127028644A patent/KR20120136413A/ko not_active Application Discontinuation
- 2005-11-14 NZ NZ555032A patent/NZ555032A/en unknown
- 2005-11-14 EP EP05849392.5A patent/EP1824988B1/fr active Active
- 2005-11-14 MX MX2007005466A patent/MX2007005466A/es active IP Right Grant
- 2005-11-14 LT LTEP11153297.4T patent/LT2371856T/lt unknown
- 2005-11-14 EP EP17201672.7A patent/EP3323829B1/fr active Active
- 2005-11-14 PT PT58493925T patent/PT1824988T/pt unknown
- 2005-11-14 LT LTEP11153300.6T patent/LT2363414T/lt unknown
- 2005-11-14 PH PH12014500352A patent/PH12014500352A1/en unknown
- 2005-11-14 CN CN201210455152.1A patent/CN103102406B/zh active Active
- 2005-11-14 CN CN2005800464698A patent/CN101124331B/zh active Active
- 2005-11-14 PT PT111533006T patent/PT2363414T/pt unknown
- 2005-11-14 HU HUE11153300A patent/HUE060016T2/hu unknown
- 2005-11-14 EP EP17170687.2A patent/EP3243834A1/fr not_active Withdrawn
- 2005-11-14 PL PL05849392T patent/PL1824988T3/pl unknown
- 2005-11-14 LT LTEP05849392.5T patent/LT1824988T/lt unknown
- 2005-11-14 ES ES05849392.5T patent/ES2633916T3/es active Active
- 2005-11-14 PL PL11153300.6T patent/PL2363414T3/pl unknown
- 2005-11-14 JP JP2007541405A patent/JP2008524117A/ja active Pending
- 2005-11-14 AU AU2005304622A patent/AU2005304622B2/en active Active
- 2005-11-14 CN CN201610201090.XA patent/CN105753968A/zh active Pending
- 2005-11-14 US US11/273,896 patent/US7632921B2/en active Active
- 2005-11-14 RU RU2007121517/10A patent/RU2423380C2/ru active
- 2005-11-14 NO NO20210454A patent/NO20210454A1/no unknown
- 2005-11-14 KR KR1020147002721A patent/KR101483917B1/ko active IP Right Grant
- 2005-11-14 ES ES11153297T patent/ES2930143T3/es active Active
- 2005-11-14 MX MX2014005051A patent/MX350293B/es unknown
- 2005-11-14 KR KR1020147018134A patent/KR101654011B1/ko active IP Right Grant
- 2005-11-14 ES ES16186901T patent/ES2821832T3/es active Active
- 2005-11-14 LT LTEP16186901.1T patent/LT3130601T/lt unknown
- 2005-11-14 PT PT111532974T patent/PT2371856T/pt unknown
- 2005-11-14 KR KR1020137007423A patent/KR101468345B1/ko active Protection Beyond IP Right Term
- 2005-11-14 NO NO20200044A patent/NO345800B1/no unknown
- 2005-11-14 ES ES11153300T patent/ES2930159T3/es active Active
- 2005-11-14 KR KR1020167023706A patent/KR101904630B1/ko active IP Right Grant
- 2005-11-14 SI SI200532308T patent/SI2363414T1/sl unknown
- 2005-11-14 BR BR122016022033A patent/BR122016022033B8/pt active IP Right Grant
- 2005-11-14 BR BRPI0517795A patent/BRPI0517795B8/pt active IP Right Grant
- 2005-11-14 EP EP16186902.9A patent/EP3153181A1/fr not_active Withdrawn
- 2005-11-14 DK DK11153300.6T patent/DK2363414T3/da active
- 2005-11-14 HU HUE11153297A patent/HUE059193T2/hu unknown
- 2005-11-14 PT PT161869011T patent/PT3130601T/pt unknown
- 2005-11-14 CN CN201610838893.6A patent/CN107082806A/zh active Pending
- 2005-11-14 SI SI200532158T patent/SI1824988T1/sl unknown
- 2005-11-14 KR KR1020077013131A patent/KR101243564B1/ko active Protection Beyond IP Right Term
- 2005-11-14 PL PL11153297.4T patent/PL2371856T3/pl unknown
- 2005-11-14 EP EP11153297.4A patent/EP2371856B1/fr active Active
- 2005-11-14 DK DK11153297.4T patent/DK2371856T3/da active
- 2005-11-14 CN CN201510612184.1A patent/CN105148287B/zh active Active
- 2005-11-14 CA CA2586379A patent/CA2586379C/fr active Active
- 2005-11-14 SI SI200532283T patent/SI3130601T1/sl unknown
- 2005-11-14 EP EP17166910.4A patent/EP3243833B1/fr active Active
- 2005-11-14 CN CN201310125428.4A patent/CN103214569B/zh active Active
- 2005-11-14 DK DK05849392.5T patent/DK1824988T3/en active
- 2005-11-14 UA UAA200706559A patent/UA95225C2/ru unknown
- 2005-11-14 SI SI200532309T patent/SI2371856T1/sl unknown
-
2007
- 2007-05-01 IL IL182903A patent/IL182903A/en active IP Right Grant
- 2007-05-08 ZA ZA200703696A patent/ZA200703696B/xx unknown
- 2007-05-11 HN HN2007015683A patent/HN2007015683A/es unknown
- 2007-06-06 MA MA29972A patent/MA29663B1/fr unknown
- 2007-06-08 HR HRP20070268AA patent/HRP20070268B1/hr active IP Right Grant
- 2007-06-12 NO NO20072997A patent/NO344606B1/no unknown
-
2008
- 2008-07-15 HK HK08107795.4A patent/HK1117875A1/xx unknown
-
2009
- 2009-08-13 US US12/540,703 patent/US9364520B2/en active Active
-
2012
- 2012-10-19 JP JP2012231926A patent/JP6109523B2/ja active Active
-
2013
- 2013-01-24 US US13/748,983 patent/US9096656B2/en active Active
- 2013-08-13 HK HK13109463.4A patent/HK1182121A1/xx unknown
-
2014
- 2014-05-11 IL IL232540A patent/IL232540A/en active IP Right Grant
- 2014-09-02 IL IL23443314A patent/IL234433B/en active IP Right Grant
-
2015
- 2015-02-09 JP JP2015022993A patent/JP6018238B2/ja active Active
- 2015-07-20 US US14/803,677 patent/US20160051633A1/en not_active Abandoned
-
2016
- 2016-06-13 HK HK16106727.9A patent/HK1218718A1/zh not_active IP Right Cessation
- 2016-12-02 JP JP2016234756A patent/JP6487895B2/ja active Active
- 2016-12-02 JP JP2016234757A patent/JP6559642B2/ja active Active
-
2017
- 2017-07-14 CY CY20171100753T patent/CY1119292T1/el unknown
-
2019
- 2019-05-07 HU HUS1900026C patent/HUS1900026I1/hu unknown
- 2019-05-07 FR FR19C1031C patent/FR19C1031I2/fr active Active
- 2019-05-08 LU LU00118C patent/LUC00118I2/fr unknown
- 2019-05-09 LT LTPA2019509C patent/LTC1824988I2/lt unknown
- 2019-05-10 NL NL300989C patent/NL300989I2/nl unknown
- 2019-05-10 CY CY2019024C patent/CY2019024I1/el unknown
- 2019-07-09 PH PH12019501613A patent/PH12019501613A1/en unknown
-
2020
- 2020-10-05 CY CY20201100928T patent/CY1123384T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29663B1 (fr) | Modification du facteur fviii en fonction du site | |
DK1487493T3 (da) | Konjugater af cytotoksiske midler og biologisk aktive peptider | |
CY1117387T1 (el) | ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ | |
DE60315454D1 (de) | Blockcopolymere auf basis von konjugierten dienen und monovinylarenen enthaltende mischungen | |
ATE305932T1 (de) | Rapanycin29-enole | |
NO20071740L (no) | Humaniserte anti-beta7-antagonister og anvendelser derav | |
CY1113798T1 (el) | Υποκατεστημενες ενωσεις διαζεπανης ως ανταγωνιστες υποδοχεα ορεξινης | |
NO20034056D0 (no) | Proliferative sykdommer | |
DE602004019546D1 (de) | Heterofunktionelle copolymere von glycerol und polyethylenglykol, ihre konjugate und zusammensetzungen | |
TR200102733T2 (tr) | IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri | |
CY1106394T1 (el) | Χαπepονινη 60.1 m.tuberculosis και χρησεις αυτης | |
CY1116415T1 (el) | Φαρμακευτικες συνθεσεις που περιλαμβανουν l-733060 για χρηση στη θεραπευτικη αγωγη καρκινικων ογκων | |
WO2009015063A8 (fr) | Procédés et compositions pour traiter des troubles associés à une fibrose en utilisant des antagonistes de l'il-17 | |
EA200300852A1 (ru) | Конъюгаты нейбластина с полимерами и способы их применения | |
WO2006065867A3 (fr) | Immunotoxine exotoxique de pseudomonas a liaison polymere | |
MXPA05013509A (es) | Polipeptidos de fusion de variante ib alfa de glucoproteina de plaquetas y metodos y uso de los mismos. | |
MXPA05005484A (es) | Metodo para mejorar las propiedaes fisico-quimicas de composiciones bituminosas y novedosas composiciones bituminosas con propiedades mejoradas y sus usos. | |
ATE409045T1 (de) | Pharmazeutische zusammensetzung enthaltend löslichen fcgamma rezeptor iib | |
ATE360420T1 (de) | VERWENDUNG VON WIRKSTOFFEN MIT µ-OPIOID-REZEPTOR AGONISTISCHER WIRKUNG UND OPIOID-REZEPTOR ANTAGONISTISCHER WIRKUNG ALS KOMBINATIONSARZNEIMITTEL ZUR KREBSBEHANDLUNG | |
MY151329A (en) | Site-directed modification of fviii | |
MY173864A (en) | Site-directed modification of fviii | |
MY181129A (en) | Site-directed modification of fviii | |
FR2832155B1 (fr) | Anticorps stimulant la production d'il-1ra | |
MXPA01009174A (es) | Antagonistas de endotelina novedosos derivados de piridazina. | |
ITFI20030238A1 (it) | Peptidi ciclici antagonisti dell'urotensina-ii |